Anxiety and dysautonomia symptoms in patients with a NaV1.7 mutation and the potential benefits of low-dose short-acting guanfacine

CONCLUSION: Our study provides further evidence for a possible pathophysiological role of Na(V)1.7 in anxiety and dysautonomia. Combined with off-target effects on Na(V) channel function, daily administration of 1 mg short-acting guanfacine may be sufficient to normalize Na(V) channel mutation-induced changes in sympathetic activity, perhaps aided by partial inhibition of Na(V)1.7 or other channel subtypes. In a broader context, expanding genetic and functional data about ion channel aberrations…

via https://pubmed.ncbi.nlm.nih.gov/38064009/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20231226010907&v=2.18.0